# Is Cannabis an Antibiotic Savior in Antibiotic-Induced Bacteremia? > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-antibiotic-properties-antibiotic-bacteremia/ > **Published:** 2019-11-26T14:22:51-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:17:43-04:00 > **Clinical Summary:** Explore cannabis antibiotic properties and their potential role in reducing antibiotic-induced bacteremia and Clostridioides difficile infection risks. --- ### ​New research shows that cannabis use is linked to decreased incidence of Clostridioides difficile infection **Clostridioides difficile infection (CDI) linked to 220,000 hospitalized patients** Clostridioides difficile (CD) is a gram-positive bacillus commonly found in soil that can cause antibiotic-associated diarrhea. Clostridioides difficile infection (CDI) is linked to 220,000 cases in hospitalized patients and is responsible for about 13,000 deaths per year in the United States. As a result, CDI creates over $4.8 billion in medical expenses per year in the United States. Affected individuals are typically younger, with an average age of 50 years. ​ A recent review gathered evidence that patients using cannabis regularly had lower odds of being diagnosed with CDI. **​Clostridioides difficile (CD) causes cell death** Clostridioides difficile is resistant to multiple antibiotics, and colonization with CD most commonly occurs following antibiotic treatment for other diseases; the resulting post-antibiotic harm to the intestinal flora promotes CDI. Its spores are easily transmitted through the fecal-oral route and are challenging to eradicate. CD produces toxins that disrupt enterocyte intercellular junctions, causing cell death and promoting transmural invasion. Typical symptoms include diarrhea followed by fever and abdominal pain. Severe CDI or fulminant CDI may be life-threatening. Once the diagnosis is confirmed, measures to prevent transmissions like isolation and strict adherence to hygiene measures must be implemented. With this work, researchers Adeyinka Charles Adejumo and Terence Ndonyi Bukong illuminated the impact of [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) on CDI incidence amongst hospitalized individuals. **Cannabidiol (CBD) effects on disorders, dysfunctions, and pathologies** Cannabinoids, considered to have antibacterial attributes, are most well-known as one of the more than 500 components in the plant cannabis. As a non-psychoactive component derived from the cannabis plant (Cannabis sativa), cannabidiol (CBD) demonstrated positive effects on several psychiatric disorders, metabolic dysfunctions, and malignant pathologies. [Basic science](https://cedclinic.com/antigen-presentation-mechanisms-cannabis-immunology/) research confirmed antibiotic properties of cannabinoids against staphylococcus aureus and protection from endotoxin-induced septic shock syndrome, as well as neurological damage from streptococcal pneumonia meningitis. In-vitro studies showed inhibition of CD conceivably through a variety of effects. Firstly, by promoting enhanced gut integrity and homeostasis. Secondly, by modulation of the intestinal microbiome composition. Evidence indicates that by shifting the microbiome balance in favor of lower firmicutes and higher bacteroidetes, cannabinoids have gut protective characteristics. Thirdly, cannabinoids were able to suppress intestinal inflammation in murine models. Lastly, cannabinoids proved to impede the toxicity of clostridium bacteria in in-vitro cultures. Nevertheless, in contrast, tetrahydrocannabinol (THC), a pharmacologically active component of cannabis, suppresses stomach acid secretion; decreased gastric acidity is sought to be an independent risk factor for CDI. **Cannabis is related to decreased CDI **This publication, [Cannabis use and risk of Clostridioides difficile infection: Analysis of 59,824 hospitalizations](https://pubmed.ncbi.nlm.nih.gov/31493498/), highlights that cannabis, in an increasing dosage, is related to decreased incidence of CDI. Still, the broader mechanism of cannabis on this disease remains ill-defined. ​ Further research into the mechanism and relationship underlying the antibiotic properties of cannabis might be fruitful. More extensive prospective cohort studies are needed to translate preclinical findings on cannabinoids and CDI to [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/). ## Authored by Dr Bjoern Langbein [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabis Compounds Show Promise Against Cancer and Viral Disease—But the Evidence Is Still Largely Preclinical](https://cedclinic.com/cannabis-compounds-medical-evidence-review-2024/) Review the latest preclinical evidence on [cannabis compounds](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/) and their potential medical benefits, including antibacterial properties. [Explore Cannabis Research](https://cedclinic.com/cannabis-compounds-medical-evidence-review-2024/) [The wide distribution of cannabinoid receptors in the gastrointestinal tract suggests cannabinoids like CBD can relieve GI pain](https://cedclinic.com/cannabinoid-receptors-gastrointestinal-tract/) Learn how cannabinoids interact with the gut and may influence [gastrointestinal health](https://cedclinic.com/ibs-treatment-safety-concerns-mortality-risk-study/) and infections. [Learn About GI Effects](https://cedclinic.com/cannabinoid-receptors-gastrointestinal-tract/) [Brain Researchers Finally Know Why Cannabis Use Increases Appetite – The Debrief](https://cedclinic.com/cannabinoids-brain-appetite-interaction/) Discover neurological insights into cannabis effects that may relate to its broader therapeutic potential. [Read Neurological Insights](https://cedclinic.com/cannabinoids-brain-appetite-interaction/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Is%20Cannabis%20an%20Antibiotic%20Savior%20in%20Antibiotic-Induced%20Bacteremia%3F&url=https%3A%2F%2Fcedclinic.com%2Fcannabis-antibiotic-properties-antibiotic-induced-bacteremia%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabis-antibiotic-properties-antibiotic-induced-bacteremia%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Is%20Cannabis%20an%20Antibiotic%20Savior%20in%20Antibiotic-Induced%20Bacteremia%3F%20https%3A%2F%2Fcedclinic.com%2Fcannabis-antibiotic-properties-antibiotic-induced-bacteremia%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).